US OptionsDetailed Quotes

ENTA241220C7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Enanta Pharmaceuticals Stock Discussion

Moomoo AI

Mar 5 20:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Moomoo AI

Feb 12 05:23

Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported And Analysts Have Been Cutting Their Estimates

Moomoo AI

Jan 18 04:42

The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Moomoo AI

Dec 17, 2023 06:41

Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.

Independent Director Of Enanta Pharmaceuticals Sold 73% Of Their Shares

Explore moomoo's "Insider Activity" for institutional sentiment

Analysts Notebook

Jul 6, 2022 07:10

Columns Top upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more

Upgrades
• $A.O. Smith (AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum (CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet (DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning (GLW.US)$ : CFRA Upgrades to Strong Buy ...

Moomoo Breakfast US

Jun 22, 2022 07:48

Columns Today's pre-market stock movers: BBIO, LZB, ORA, DOW and more

Gainers:
• $La-Z-Boy (LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals (ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer (PFE.US)$)
• $Ikena Oncology (IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma (BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech (KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...

Moomoo Breakfast US

Jun 1, 2022 07:21

Columns Today's pre-market stock movers: CRM, WB, LI, NIO and more

Gainers:
• $Victoria's Secret (VSCO.US)$ +10.4% (In reaction to earnings)
• $Salesforce (CRM.US)$ +9.0% (In reaction to earnings)
• $Navigator (NVGS.US)$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo (WB.US)$ +4.7% (In reaction to earnings)
• $CAE Inc (CAE.US)$ +4.7% (In reaction to earnings)
• $Laredo Petroleum (LPI.US)$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics (AXSM.US)$ +3.1% (Late-Breaking Presentations of P...

Analysts Notebook

Jun 1, 2022 05:51

Columns Top upgrades and downgrades on 6/1

Upgrades
• $Blueprint Medicines (BPMC.US)$ : Jefferies Upgrades to Buy from Hold - PT $78 (from $88)
• $CatchMark Timber Trust Inc (CTT.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $Danaher (DHR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $310 (from $299)
• $Enanta Pharmaceuticals (ENTA.US)$ : Evercore ISI Upgrades to In Line from Underperform - PT $39 (from $35)
• $FEMSA (FMX.US)$ : Bradesco BBI Upgrades to Outperform f...

Moomoo Breakfast US

May 19, 2022 07:15

Columns Today's pre-market stock movers: GOOS, TSLA, KSS, UAA and more

Gainers:
• $Rocket Pharmaceuticals (RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose (GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies (SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...

No comment yet